Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.07.2018 | Case report

Dasabuvir/ombitasvir/paritaprevir/ritonavir

Development of ombitasvir resistance in hepatitis C virus infection leading to real-life 3D therapy failure: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Marascio N, et al. Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling. Journal of Medical Virology 90: 1257-1263, No. 7, Jul 2018. Available from: URL: http://doi.org/10.1002/jmv.25073- Italy Marascio N, et al. Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling. Journal of Medical Virology 90: 1257-1263, No. 7, Jul 2018. Available from: URL: http://​doi.​org/​10.​1002/​jmv.​25073- Italy
Metadaten
Titel
Dasabuvir/ombitasvir/paritaprevir/ritonavir
Development of ombitasvir resistance in hepatitis C virus infection leading to real-life 3D therapy failure: case report
Publikationsdatum
01.07.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-48785-9

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Minocycline

Case report

Antineoplastics

Case report

Mesalazine

Case report

Dexamethasone